Tenascin staining positivity and the survival of patients with invasive breast carcinoma.
Tenascin immunohistochemical staining was investigated in 82 patients with primary invasive breast carcinoma followed for at least 5 years after surgery; the staining was analyzed in relation to clinicopathological factors. An intense tenascin staining pattern was noted in 59 patients (72%), but no definite correlation was found between tenascin positivity and clinical stage, lymph node metastasis, or estrogen receptor status. However, tenascin-positive patients had a significantly better prognosis than tenascin-negative patients. Tenascin staining may therefore be a useful marker for predicting the survival of breast cancer patients.
Shoji
T
T
Department of Pathology, Kansai Medical University, Osaka, Japan.
Kamiya
T
T
Tsubura
A
A
Hamada
Y
Y
Hatano
T
T
Hioki
K
K
Morii
S
S
D001943:Breast Neoplasms / Q000737:chemistry* / Q000401:mortality* / Q000473:pathology; D015816:Cell Adhesion Molecules, Neuronal / Q000032:analysis*; D016326:Extracellular Matrix Proteins / Q000032:analysis*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D011960:Receptors, Estrogen / Q000032:analysis; D015996:Survival Rate; D019063:Tenascin
D015816:Cell Adhesion Molecules, Neuronal; D016326:Extracellular Matrix Proteins; D011960:Receptors, Estrogen; D019063:Tenascin